Hyglos introduced EndoLISA® – a new method for efficient and reliable determination of endotoxins (LPS) based on the proprietary phage ligand technology. An enormous advantage of Hyglos’ ELISA-based assay is the heterogenous microtiter plate based format (96-well microplate with 8-well strips). The LPS from the sample is specifically immobilized for detection while interfering ingredients such as proteins or beta glucans are removed by a washing step. This enables the Hyglos method to precisely determine the endotoxin without matrix effects, without dilution and with a broad pH tolerance. The detection reaction in EndoLISA® is based on Recombinant Factor C (rFC). The world’s first endotoxin detection system based on ELISA-technology overcoming limitations of traditional methods, such as the LAL (Limulus amebocyte lysate). A highly robust method with unprecedented salt and detergent tolerance. Developed and intended for complex sample matrices such as biopharmaceuticals; proteins, antibodies and vaccines. The data below will prove that EndoLISA® can outperform the LAL Assay for complex sample matrixes while robust enough to handle simple samples. The following data below is a list of customer applications using EndoLISA® vs. the LAL Assay for specific product types. More information can be requested from Hyglos GmbH.
No comments:
Post a Comment